SCHEMBL4054464

SCHEMBL4054464

CCn1nc(-c2ccccc2)c(-c2csc(-c3ccccn3)n2)c(Nc2cnccc2C)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.40
ADORA2A P29274 1/20 0.40
PDE4B Q07343 5/20 0.36
ADORA3 P0DMS8 1/20 0.36
TBXAS1 P24557 1/20 0.36
CYP19A1 P11511 2/20 0.35
PDE4A P27815 3/20 0.35
PDE4C Q08493 3/20 0.35
PDE4D Q08499 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PDE10A Q9Y233 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
KRAS P01116 1/20 0.34
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4057374 0.92 CYP19A1 (0.40) ADORA1ADORA2APDE4BADORA3TBXAS1
SCHEMBL4057217 0.88 CYP19A1 (0.43) ADORA1ADORA2APDE4BADORA3TBXAS1
SCHEMBL4049566 0.87 CYP19A1 (0.46) PDE4BCYP19A1PDE4APDE4CPDE4D
SCHEMBL4051865 0.79 CYP19A1 (0.46) ADORA1PDE4BADORA3TBXAS1CYP19A1
SCHEMBL5236994 0.79 ADORA1 (0.47) ADORA1ADORA2APDE4BADORA3TBXAS1
SCHEMBL5751592 0.79 PDE4B (0.37) ADORA1ADORA2APDE4BCYP19A1
SCHEMBL4055240 0.75 CYP19A1 (0.39) ADORA1ADORA2APDE4BADORA3TBXAS1
SCHEMBL4052875 0.75 CYP19A1 (0.49) PDE4BTBXAS1CYP19A1NPC1RAB9A
SCHEMBL4054444 0.74 PDE4B (0.56) ADORA1PDE4BADORA3TBXAS1PDE4A
SCHEMBL4052369 0.74 CYP19A1 (0.42) ADORA1ADORA3TBXAS1CYP19A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511038-B2 Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors LABORATORIOS ALMIRALL S.A. (ES) 2009-03-31 US disclosed
US-20070197536-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197536-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease PDE12, PDE4A, PDE7A ADORA1 409/4885ADORA2A 729/4885PDE4B 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.